InnoCare Announces FDA Approval of Clinical Trial for BCL2 Inhibitor Mesutoclax in AML and MDS
July 14, 2025 ,InnoCare Pharma announced that FDA has approved the Investigational New Drug application to conduct the clinical trial of BCL2 inhibitor mesutoclax in combination with azacitidine for the treatment of myeloid malignancies.
July 14, 2025
by PharmaSources
Recent Job Cuts in FDA and other pharmaceutical companies, and the impact on the industry
The pharma industry faces downsizing in various areas, where a number of employees are fired or relieved of their duties.In addition to the manufacturing industry, the FDA also faces job and funding cuts.
May 15, 2025
by Muhammad Asim Niazi
Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China
This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
April 28, 2025
by Kevin
NAD+ Application in Pharmaceutical Industry and Regulatory Status in Multiple Countries and Markets
This article highlights key applications, clinical trial developments, and regulatory classifications of NAD⁺ and its derivatives across major global markets.
April 25, 2025
by Nurah Ekhlaque
Ethical and Regulatory Considerations in Personalized Medicine
Personalized medicine is revolutionizing healthcare by tailoring medical treatments to individual genetic profiles, lifestyles, and environmental factors.
April 7, 2025
by Saher Haider
Pharmaceutical Cold Chain Monitoring
Cold Chain is a supply chain system where product specific temperature is maintained while the it is in storage, transportation and distribution.
March 31, 2025
by Muhammad Asim Niazi
Henlius Receives Orphan Drug Designation for HLX22 in the U.S. for Gastric Cancer
Henlius announced that FDA has granted ODD for HLX22, the company's innovative anti-HER2 mAb for the treatment of gastric cancer.
March 19, 2025
by PR Newswire
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer
Shanghai Henlius Biotech announced that FDA has granted ODD for HLX22 for the treatment of gastric cancer.
March 19, 2025
by PR Newswire
What is Clinical Hold and how do you deal with it?
A clinical hold is implemented for IND which is a drug stage under clinical trials to investigate its efficacy & safety, and has not been officially allowed to market & used by patients.
March 5, 2025
by Muhammad Asim Niazi
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 in Squamous Non-Small Cell Lung Cancer
Innovent Receives FDA for IBI363 in Squamous Non-Small Cell Lung Cancer
February 17, 2025
by PR Newswire
Navi Medical Technologies' Neonav® ECG Tip Location System Receives FDA 510(k) Clearance
FDA 510(k) Clearance Revolutionising Vascular Access Care for Critically Ill Newborns and Children
February 17, 2025
by PR Newswire
FDA Clears World's First Mobile App for Contactless Pulse Rate Measurement
On Jan. 26, Hong Kong - based PanopticAI announced getting FDA 510(k) clearance for its contactless vital signs monitoring software, turning mobile devices into medical - grade monitors.
January 26, 2025
by PharmaSources